“End-to-End” Strategies Achieve Better Enrollment, Diversity, and Data Collection in Clinical Trials
The revolution in cancer drug development has a caveat: Only a fraction of eligible patients take part in clinical trials. Historically, findings from studies estimate that the share of eligible patients taking part in trials is 5% or less, although …